RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
-0.75%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$4.76B
AUM Growth
+$4.76B
(-5.8%)
Cap. Flow
+$78.2M
Cap. Flow
% of AUM
1.64%
Top 10 Holdings %
Top 10 Hldgs %
26.26%
Holding
166
New
11
Increased
69
Reduced
16
Closed
13
Top Buys
| 1 |
Baxter International
BAX
|
$36.2M |
| 2 |
Warby Parker
WRBY
|
$34.5M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
$30.3M |
| 4 |
Immuneering
IMRX
|
$28.9M |
| 5 |
Ascendis Pharma
ASND
|
$26.5M |
Top Sells
| 1 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$68.6M |
| 2 |
Ardelyx
ARDX
|
$39.8M |
| 3 |
Biogen
BIIB
|
$39.3M |
| 4 |
Boston Scientific
BSX
|
$34.2M |
| 5 |
PPD
PPD, Inc. Common Stock
PPD
|
$31.1M |
Sector Composition
| 1 | Healthcare | 93.53% |
| 2 | Consumer Staples | 1.58% |
| 3 | Industrials | 0.82% |
| 4 | Financials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Alnylam Pharmaceuticals
ALNY
$58.5B
| $58.7M | 1.23% | 311,000 +11,000 | +4% | +$2.08M |
|
27
Evolent Health
EVH
$1.12B
| $58.1M | 1.22% | 1,875,000 +175,957 | +10% | +$5.45M |
|
28
Pacira BioSciences
PCRX
$1.2B
| $56M | 1.18% | 1,000,000 -25,000 | -2% | -$1.4M |
|
29
Exact Sciences
EXAS
$8.98B
| $54.4M | 1.14% | 570,000 | – | – |
|
30
Prothena Corp
PRTA
$441M
| $50.6M | 1.06% | 710,430 -239,661 | -25% | -$17.1M |
|
31
Teleflex
TFX
$5.59B
| $49M | 1.03% | 130,000 | – | – |
|
|
KRTX
32
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $47.9M | 1.01% | 391,917 +5,299 | +1% | +$648K |
|
33
Arvinas
ARVN
$568M
| $47.5M | 1% | 577,500 -48,600 | -8% | -$3.99M |
|
|
CERE
34
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $47.2M | 0.99% | 1,600,589 +583,644 | +57% | +$17.2M |
|
|
SWAV
35
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $45.3M | 0.95% | 220,000 | – | – |
|
36
Acadia Healthcare
ACHC
$2.12B
| $45.3M | 0.95% | 710,000 +10,000 | +1% | +$638K |
|
|
VERV
37
DELISTED
Verve Therapeutics
VERV
| $45.3M | 0.95% | 962,826 | – | – |
|
38
Kymera Therapeutics
KYMR
$2.95B
| $43.1M | 0.91% | 732,927 +106,400 | +17% | +$6.25M |
|
39
Health Catalyst
HCAT
$239M
| $42.5M | 0.89% | 850,000 +65,000 | +8% | +$3.25M |
|
|
SGEN
40
DELISTED
Seagen Inc. Common Stock
SGEN
| $42.5M | 0.89% | 250,000 | – | – |
|
41
Penumbra
PEN
$10.6B
| $39.3M | 0.83% | 147,500 | – | – |
|
|
ACCD
42
DELISTED
Accolade, Inc. Common Stock
ACCD
| $38.9M | 0.82% | 923,000 +258,000 | +39% | +$10.9M |
|
43
Encompass Health
EHC
$12.3B
| $37.5M | 0.79% | 500,000 | – | – |
|
44
Travere Therapeutics
TVTX
$1.56B
| $36.3M | 0.76% | 1,496,817 +2,653 | +0.2% | +$64.3K |
|
|
45
Baxter International
BAX
$12.7B
| $36.2M | 0.76% | +450,000 | New | +$36.2M |
|
|
46
Warby Parker
WRBY
$3.2B
| $34.5M | 0.73% | +650,000 | New | +$34.5M |
|
|
LENZ
47
LENZ Therapeutics
LENZ
$1.1B
| $34M | 0.72% | 2,076,710 -75,028 | -3% | -$1.23M |
|
|
XENT
48
DELISTED
Intersect ENT, Inc
XENT
| $33.2M | 0.7% | 1,220,000 | – | – |
|
49
Sarepta Therapeutics
SRPT
$1.78B
| $32.4M | 0.68% | 350,000 +21,250 | +6% | +$1.97M |
|
|
ALLK
50
DELISTED
Allakos
ALLK
| $32.4M | 0.68% | 305,706 | – | – |
|